Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B

Chao Wei Hsu; Charisse Yeh; Chau Ting Yeh

doi:10.1002/jmv.25443

Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B

Chao Wei Hsu, Charisse Yeh, Chau Ting Yeh^*

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

2 Scopus citations

Abstract

In patients with chronic hepatitis B (CHB), withdrawal of nucleos(t)ide analogues (NAs) can put patients at risk of hepatitis relapses. Here, we examined a dose-reducing strategy. From March 2008 to September 2016, 48 patients with CHB who had received full-dose NA (35 entecavir; 13 tenofovir) and achieved complete virological response (lasting for >1 year), were placed on a reduced dose of antivirals (twice a week) subsequently. In a median follow-up period of 33.2 months, only one patient experienced a virological but not biochemical breakthrough. No deterioration of estimated glomerular filtration rate was found. This strategy could be used in areas where full dose, lifelong treatment is unachievable.

Original language	English
Pages (from-to)	1360-1363
Number of pages	4
Journal	Journal of Medical Virology
Volume	91
Issue number	7
DOIs	https://doi.org/10.1002/jmv.25443
State	Published - 07 2019

Bibliographical note

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Keywords

entecavir
estimated glomerular filtration rate
liver failure
tenofovir

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jmv.25443

Cite this

@article{6c984341425a408e892b043195f50e8a,

title = "Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B",

abstract = "In patients with chronic hepatitis B (CHB), withdrawal of nucleos(t)ide analogues (NAs) can put patients at risk of hepatitis relapses. Here, we examined a dose-reducing strategy. From March 2008 to September 2016, 48 patients with CHB who had received full-dose NA (35 entecavir; 13 tenofovir) and achieved complete virological response (lasting for >1 year), were placed on a reduced dose of antivirals (twice a week) subsequently. In a median follow-up period of 33.2 months, only one patient experienced a virological but not biochemical breakthrough. No deterioration of estimated glomerular filtration rate was found. This strategy could be used in areas where full dose, lifelong treatment is unachievable.",

keywords = "entecavir, estimated glomerular filtration rate, liver failure, tenofovir",

author = "Hsu, {Chao Wei} and Charisse Yeh and Yeh, {Chau Ting}",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2019",

month = jul,

doi = "10.1002/jmv.25443",

language = "英语",

volume = "91",

pages = "1360--1363",

journal = "Journal of Medical Virology",

issn = "0146-6615",

publisher = "John Wiley and Sons Inc",

number = "7",

}

TY - JOUR

T1 - Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B

AU - Hsu, Chao Wei

AU - Yeh, Charisse

AU - Yeh, Chau Ting

PY - 2019/7

Y1 - 2019/7

N2 - In patients with chronic hepatitis B (CHB), withdrawal of nucleos(t)ide analogues (NAs) can put patients at risk of hepatitis relapses. Here, we examined a dose-reducing strategy. From March 2008 to September 2016, 48 patients with CHB who had received full-dose NA (35 entecavir; 13 tenofovir) and achieved complete virological response (lasting for >1 year), were placed on a reduced dose of antivirals (twice a week) subsequently. In a median follow-up period of 33.2 months, only one patient experienced a virological but not biochemical breakthrough. No deterioration of estimated glomerular filtration rate was found. This strategy could be used in areas where full dose, lifelong treatment is unachievable.

AB - In patients with chronic hepatitis B (CHB), withdrawal of nucleos(t)ide analogues (NAs) can put patients at risk of hepatitis relapses. Here, we examined a dose-reducing strategy. From March 2008 to September 2016, 48 patients with CHB who had received full-dose NA (35 entecavir; 13 tenofovir) and achieved complete virological response (lasting for >1 year), were placed on a reduced dose of antivirals (twice a week) subsequently. In a median follow-up period of 33.2 months, only one patient experienced a virological but not biochemical breakthrough. No deterioration of estimated glomerular filtration rate was found. This strategy could be used in areas where full dose, lifelong treatment is unachievable.

KW - entecavir

KW - estimated glomerular filtration rate

KW - liver failure

KW - tenofovir

UR - http://www.scopus.com/inward/record.url?scp=85062792296&partnerID=8YFLogxK

U2 - 10.1002/jmv.25443

DO - 10.1002/jmv.25443

M3 - 文章

C2 - 30817845

AN - SCOPUS:85062792296

SN - 0146-6615

VL - 91

SP - 1360

EP - 1363

JO - Journal of Medical Virology

JF - Journal of Medical Virology

IS - 7

ER -

Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this